Target intelligence / Profile preview

Retinoic acid response element (RARE) (RARE)

Target
RARE
Molecular classification
Other, DNA motif, Cis-regulatory element
01

Overview

Retinoic acid response elements (RAREs) are specific cis-regulatory DNA sequences located within the promoter or enhancer regions of genes that are transcriptionally regulated by retinoic acid (RA) (Cunningham & Duester, 2015). These motifs typically consist of two direct repeats of the consensus hexameric sequence 5'-PuGGTCA-3', most commonly separated by five nucleotides (DR5), though spacers of one (DR1) or two (DR2) nucleotides also occur (Chambon, 1996). RAREs serve as the primary binding sites for heterodimers of the retinoic acid receptor (RAR) and the retinoid X receptor (RXR). In the absence of ligand, the RAR/RXR complex binds to the RARE and recruits corepressor proteins and histone deacetylases to maintain a repressed chromatin state. Upon binding of a retinoid ligand, such as all-trans retinoic acid (ATRA), the receptors undergo a conformational change that triggers the release of corepressors and the recruitment of coactivators, leading to the induction of gene expression (Siddikuzzaman et al., 2011). This regulatory mechanism is essential for controlling cell differentiation, embryonic development, and tissue homeostasis. Dysregulation of RARE-mediated signaling is a hallmark of certain diseases, most notably acute promyelocytic leukemia (APL), where the PML-RARalpha fusion protein interferes with normal RARE binding and gene activation (Gudas & Wagner, 2011). Therapeutic agents like tretinoin and bexarotene exert their effects by modulating the activity of receptors bound to these DNA motifs.

Other names
RARERetinoic acid response elementDR5DR2DR1Retinoid response element
02

Mechanism of action

Ligand-induced recruitment of retinoic acid receptors (RAR/RXR) to DNA motifs to modulate transcription of target genes.

03

Biological functions

Signal transductionCell cycleApoptosisCell proliferationOther
04

Disease associations

CancerInflammationOther
05

Safety considerations

TeratogenicityRetinoic acid syndrome (Differentiation syndrome)Hypervitaminosis AMucocutaneous toxicity
06

Interacting drugs

Tretinoin

6 more in the full profile.

07

Biomarkers

PML-RARA fusion proteinRAR-beta mRNA expression levelsCRABP2 expressionCYP26A1 induction

Beyond the preview

Go deeper on Retinoic acid response element (RARE) (RARE).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Retinoic acid response element (RARE) (RARE).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call